Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Dancey

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Nature Reviews. Clinical Oncology|March 18, 2010
mTOR signaling and drug development in cancerJanet Dancey
Clinical Biochemistry|March 20, 2012
Genomics, personalized medicine and cancer practiceJanet Dancey
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Epidermal growth factor receptor inhibitors in clinical developmentJanet Dancey
Nature Reviews. Drug Discovery|April 2, 2003
Issues and progress with protein kinase inhibitors for cancer treatmentJanet Dancey, Edward A Sausville
Oncotargets and Therapy|March 16, 2012
Targeted agents for the treatment of metastatic melanomaJose G Monzon, Janet Dancey
The Oncologist|February 16, 2012
Retinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literatureJose G Monzon, Nazik Hammad, Samuel D Stevens, et al.
Statistics in Medicine|May 24, 2005
Dose escalation trial designs based on a molecularly targeted endpointSally Hunsberger, Lawrence V Rubinstein, Janet Dancey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Multinomial phase II trial designsBoris Freidlin, Janet Dancey, Edward L Korn, et al.
Lung Cancer (Amsterdam, Netherlands)|January 24, 2004
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trialJanet Dancey, Frances A Shepherd, Richard J Gralla, et al.
Clinical Trials (London, England)|January 11, 2019
Conducting clinical trials-costs, impacts, and the value of clinical trials networks: A scoping reviewColene Bentley, Sonya Cressman, Kim van der Hoek, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Nature Reviews. Clinical Oncology|March 18, 2010
mTOR signaling and drug development in cancerJanet Dancey
Clinical Biochemistry|March 20, 2012
Genomics, personalized medicine and cancer practiceJanet Dancey
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Epidermal growth factor receptor inhibitors in clinical developmentJanet Dancey
Nature Reviews. Drug Discovery|April 2, 2003
Issues and progress with protein kinase inhibitors for cancer treatmentJanet Dancey, Edward A Sausville
Oncotargets and Therapy|March 16, 2012
Targeted agents for the treatment of metastatic melanomaJose G Monzon, Janet Dancey
The Oncologist|February 16, 2012
Retinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literatureJose G Monzon, Nazik Hammad, Samuel D Stevens, et al.
Statistics in Medicine|May 24, 2005
Dose escalation trial designs based on a molecularly targeted endpointSally Hunsberger, Lawrence V Rubinstein, Janet Dancey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Multinomial phase II trial designsBoris Freidlin, Janet Dancey, Edward L Korn, et al.
Lung Cancer (Amsterdam, Netherlands)|January 24, 2004
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trialJanet Dancey, Frances A Shepherd, Richard J Gralla, et al.
Clinical Trials (London, England)|January 11, 2019
Conducting clinical trials-costs, impacts, and the value of clinical trials networks: A scoping reviewColene Bentley, Sonya Cressman, Kim van der Hoek, et al.
Pageof 8